Thanks to $30 million from a clinical stage biotech company, the M.D. Anderson Cancer Center has started a new biopharmaceutical firm to find treatments for multiple cancers.
The University of Texas M.D. Anderson Cancer Center has partnered with Palo Alto, California-based BridgeBio Inc. to launch Navire Pharmaceuticals, which will develop small-molecule inhibitors to treat genetically driven and treatment-resistant cancer, according to an Oct. 4 press release.
Navire expects to begin clinical…
Houston Biz Journal
Biotech co. provides M to start new biopharmaceutical firm with M.D. Anderson